← Back to Search

Local Anesthetic

Liposomal bupivacaine for Sternotomy

Phase 1
Waitlist Available
Led By Jared Staab, DO
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours post-surgery
Awards & highlights

Study Summary

This trial is testing a new longer-acting local anesthetic to see if it is more effective than the standard in managing pain after surgery that involves opening the sternum.

Eligible Conditions
  • Sternotomy
  • Pain Management

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours post-surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Morphine
Secondary outcome measures
Delirium
Presence of sternal wound infection
Time to extubation in minutes will be retrieved via the electronic medical record

Trial Design

2Treatment groups
Active Control
Group I: Liposomal bupivacaineActive Control1 Intervention
Exparel (266mg) given by surgeon just prior to sternal closure
Group II: BupivacaineActive Control1 Intervention
40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
460 Previous Clinical Trials
169,035 Total Patients Enrolled
Jared Staab, DOPrincipal Investigator - University of Kansas Medical Center
University of Kansas Medical Center

Media Library

Liposomal Bupivacaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04585867 — Phase 1
Sternotomy Research Study Groups: Liposomal bupivacaine, Bupivacaine
Sternotomy Clinical Trial 2023: Liposomal Bupivacaine Highlights & Side Effects. Trial Name: NCT04585867 — Phase 1
Liposomal Bupivacaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04585867 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what cases is Bupivacaine administered as a medical treatment?

"Bupivacaine is routinely employed to address perphigus, but has also been known to help individuals suffering from acute nonspecific tenosynovitis, general anesthesia, and lupus erythematosus cell."

Answered by AI

How many individuals have enrolled in this research endeavor?

"Affirmative. According to the information displayed on clinicaltrials.gov, this experimental trial is actively recruiting participants and was initially posted October 11th 2017 with a recent update occurring twelve days ago. 80 volunteers are needed from one medical facility for the study's completion."

Answered by AI

Have any other medical studies utilized Bupivacaine as an active agent?

"At present, 109 research projects related to bupivacaine are underway. Of these tests, 18 have progressed to the advanced phase 3 stage. Trials for this drug can be found at 144 different medical sites located primarily in Philadelphia, Pennsylvania."

Answered by AI
~11 spots leftby Apr 2025